Constellation, Genentech, Roche deal

Roche’s Genentech unit declined to exercise a one-time option to acquire Constellation. Genentech gained the option under a 2012 deal to discover and develop small molecules targeting multiple epigenetic target classes. Constellation said Genentech was interested in Constellation’s two lead cancer programs, which are in Phase I testing, and planned to shut down the rest of the company. ...